Seroprevalence of rubella among Jordanian women of childbearing age.
This study was conducted to assess immunity (seroprevalence) to rubella among Jordanian women of childbearing age. A multistage cluster sampling was used to recruit 1125 women of childbearing age (15-49 year) from the 12 Governorates of Jordan. Anti-rubella antibody titers were measured using enzyme-linked immunoassays. The overall immunity rate to rubella among women in childbearing age was 90.9% (CI: 88.8-92.9). However, the immunity rate was significantly lower in younger women aged 15-19 years (83%) compared to the whole cohort (P</=0.001) which means potential increased risk for congenital rubella syndrome (CRS). Immunity rates did not differ between regions and between urban and rural areas. Since the main priority is to decrease CRS among relatively susceptible cohorts, we recommend modifying the existing Expanded Program on Immunization with inclusion of a second dose of rubella vaccine at school entry (6 years of age) to decrease circulation of the virus among susceptible young females. We also recommend yearly catch-up school vaccination of young females entering the 10th grade for the next 10 years. Strengthening of rubella and CRS surveillance programs is also recommended in parallel with pre-marriage counseling regarding rubella and CRS for young females.
Jarour
Najwa
N
Directorate of Diseases Control and Prevention, Ministry of Health, Amman, Jordan. jarour2002@yahoo.com
Hayajneh
Wail A
WA
Balbeesi
Adel
A
Otoom
Haidar
H
Al-Shurman
Abdullah
A
Kharabsheh
Sa'ad
S
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D007597:Jordan / Q000453:epidemiology; D008875:Middle Aged; D015995:Prevalence; D012409:Rubella / Q000453:epidemiology* / Q000276:immunology / Q000821:virology; D012410:Rubella Syndrome, Congenital / Q000517:prevention & control; D012411:Rubella Vaccine / Q000008:administration & dosage; D012412:Rubella virus / Q000276:immunology*; D016036:Seroepidemiologic Studies
D000914:Antibodies, Viral; D012411:Rubella Vaccine